American Journal of Hematology
10 articles tagged "American Journal of Hematology"
← Across Medicine
Glofitamab Shows High Response Rates in Refractory Aggressive B-Cell Lymphoma
Real-world data link baseline CD4+ effector T cells and early CD8+ expansion to improved outcomes with bispecific antibody therapy.
Early Chelation Prevents Cardiac Iron Overload in Diamond–Blackfan Anemia
A retrospective study of 64 infants shows that initiating chelation at a median age of 18 months reduces ferritin and protects the heart.
Molecular Monitoring Predicts Mantle Cell Lymphoma Relapse Months Before Imaging
Next-generation sequencing of residual disease identifies relapse 6.5 months earlier than PET-CT after CAR T-cell therapy.
PD-1 Inhibitors Improve Survival in First-Line NK/T-Cell Lymphoma Treatment
Adding PD-1 inhibitors to asparaginase-based therapy reduces mortality risk by 45 percent in patients with high-risk extranodal disease.
Glofitamab Shows 75% Response Rate in Refractory CNS Lymphoma
Real-world data demonstrate measurable drug penetration and the utility of liquid biopsy for monitoring treatment response.
Alternating Venetoclax Triplets Extend Survival in Older AML Patients
A phase 2 trial shows a 45% five-year survival rate and high rates of deep molecular remission using an alternating low-intensity regimen.
Liver Stiffness Better Reflects Cumulative Hepatic Injury Than Iron Concentration in Thalassemia
Elastography identifies advanced fibrosis in transfusion-dependent patients even when iron levels are well-controlled by chelation therapy.
Plasma Heme Assay Predicts Mortality Risk in Sickle Cell Disease
Direct quantification of heme species identifies patients with severe hemolysis and exhausted scavenging capacity better than indirect markers.
FLAG-Ida Achieves 57 Percent Remission in Relapsed Acute Myeloid Leukemia
A 26-year multicenter study of 1,079 patients confirms the intensive regimen as an effective bridge to transplant for fit adults.
Hodgkin Lymphoma Survivors Face Quality of Life Deficits Decades After Diagnosis
A nationwide study shows persistent fatigue and dyspnea in survivors compared to the general population, even 10 years post-treatment.